Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0GKZML
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CN112341521B+ADC-5
|
|||||
| Synonyms |
CN112341521B+ADC-5
Click to Show/Hide
|
|||||
| Organization |
Jiangsu Hansoh Pharmaceutical Group Co Ltd; Shanghai Hansoh Biomedical Co Ltd
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4.3
|
|||||
| Structure |
|
|||||
| Antibody Name |
Nimotuzumab
|
Antibody Info | ||||
| Antigen Name |
V-set domain-containing T-cell activation inhibitor 1 (VTCN1)
|
Antigen Info | ||||
| Payload Name |
Topo1 inhibitor D
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase I (TOP1)
|
Target Info | ||||
| Linker Name |
CN112341521B+Linker3
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
I-5
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC54) |
20.44 ug/mL
|
|||
| Method Description |
Add the antibody-coupled drug product C or nimotuzumab with a specified concentration to the cells, incubate for 3 days, and then add 40uL of Promega CellTiter-Glo reagent (Promega catalog number G968B). Subsequently, the chemiluminescence reading from CellTiter-Glo reagent was read to determine IC50 (54%% inhibitory concentration).
|
||||
| In Vitro Model | Lung adenocarcinoma | HCC-827 cells | CVCL_2063 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC53) |
1181 ug/mL
|
|||
| Method Description |
Add the antibody-coupled drug product C or nimotuzumab with a specified concentration to the cells, incubate for 3 days, and then add 40uL of Promega CellTiter-Glo reagent (Promega catalog number G968B). Subsequently, the chemiluminescence reading from CellTiter-Glo reagent was read to determine IC50 (53%% inhibitory concentration).
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1975 cells | CVCL_1511 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC52) |
64.44 ug/mL
|
|||
| Method Description |
Add the antibody-coupled drug product C or nimotuzumab with a specified concentration to the cells, incubate for 3 days, and then add 40uL of Promega CellTiter-Glo reagent (Promega catalog number G968B). Subsequently, the chemiluminescence reading from CellTiter-Glo reagent was read to determine IC50 (52%% inhibitory concentration).
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC51) |
25.96 ug/mL
|
|||
| Method Description |
Add the antibody-coupled drug product C or nimotuzumab with a specified concentration to the cells, incubate for 3 days, and then add 40uL of Promega CellTiter-Glo reagent (Promega catalog number G968B). Subsequently, the chemiluminescence reading from CellTiter-Glo reagent was read to determine IC50 (51%% inhibitory concentration).
|
||||
| In Vitro Model | Squamous cell carcinoma of the oral tongue, Tongue squamous cell carcinoma | CAL33 cells | CVCL_1108 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
1.69 ug/mL
|
|||
| Method Description |
Add the antibody-coupled drug product C or nimotuzumab with a specified concentration to the cells, incubate for 3 days, and then add 40uL of Promega CellTiter-Glo reagent (Promega catalog number G968B). Subsequently, the chemiluminescence reading from CellTiter-Glo reagent was read to determine IC50 (50%% inhibitory concentration).
|
||||
| In Vitro Model | Hypopharyngeal squamous cell carcinoma | FaDu cells | CVCL_1218 | ||
References